The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).
 
Tetsuya Sakai
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; MSD (Inst); Novartis; Pfizer
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Taku Nakagawa
No Relationships to Disclose
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Chugai Pharma; MSD
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Novartis
 
Hidetoshi Itani
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD; Taiho Pharmaceutical
Speakers' Bureau - Lilly Japan
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD
 
Masato Shingyoji
No Relationships to Disclose
 
Atsushi Nakamura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD
Consulting or Advisory Role - Kyowa Hakko Kirin
 
Ryo Toyozawa
Honoraria - Bristol-Myers Squibb; MSD; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Pfizer (Inst); Takeda (Inst)
 
Masahide Mori
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Takeshi Tuda
No Relationships to Disclose
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomohiro Sakamoto
No Relationships to Disclose
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck KGaA; Merck Sharp & Dohme; Nippon Kayaku; Nitto Denko; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst)
 
Takaya Ikeda
No Relationships to Disclose
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hibiki Udagawa
Honoraria - Abbvie; Amco; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie; Amgen; Daiichi Sankyo; MSD
 
Keisuke Kirita
Honoraria - Amco; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD Oncology; Novartis; Olympus; Pfizer
Research Funding - Chugai Pharma; MSD Oncology; Pfizer
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kirin Pharmaceuticals; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Shionogi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Pfizer (Inst)
 
Koichi Goto
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; IQvia; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo